SCHEDULE 13G 0001176309 XXXXXXXX LIVE Common Stock par value $0.0001 per share 01/13/2025 0001820190 Scilex Holding Company 80880W106 960 San Antonio Road, Palo Alto, CA 94303 Rule 13d-1(c) Oramed Pharmaceuticals Inc. DE 15500000.00 0.00 15500000.00 0.00 15500000.00 N 6.2 CO Note to Rows 5, 7, 9: Comprised of (i) 9,000,000 shares of common stock, par value $0.0001 per share ("Common Stock"), of Scilex Holding Company (the "Issuer"), and (ii) 6,500,000 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of the date on which this Schedule 13G has been filed with the Securities and Exchange Commission ("SEC"). Note to Row 11: Percent of class beneficially owned is calculated based on 243,312,885 shares of Common Stock outstanding as of January 6, 2025 as represented by the Issuer, plus 6,500,000 shares of Common Stock issuable upon exercise of warrants held by the Reporting Person that are exercisable within 60 days of the date on which this Schedule 13G has been filed with the SEC. Scilex Holding Company 960 San Antonio Road, Palo Alto, California, 94303 Oramed Pharmaceuticals Inc. ("Oramed") 1185 Avenue of the Americas, Third Floor, New York, NY 10036 Delaware Y The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The amount beneficially owned is comprised of (i) 9,000,000 shares of common stock, par value $0.0001 per share ("Common Stock"), of Scilex Holding Company (the "Issuer"), and (ii) 6,500,000 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of the date on which this Schedule 13G has been filed with the Securities and Exchange Commission ("SEC"). The information required by Item 4(b) is set forth in Row 11 of the cover page for the Reporting Person and is incorporated herein by reference. The percent of class beneficially owned reported in Row 9 of the cover page for the Reporting Person is calculated based on 243,312,885 shares of Common Stock outstanding as of January 6, 2025 as represented by the Issuer, plus 6,500,000 shares of Common Stock issuable upon exercise of warrants held by the Reporting Person that are exercisable within 60 days of the date on which this Schedule 13G has been filed with the SEC. This calculation results in 6.2 15,500,000 0 15,500,000 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Oramed Pharmaceuticals Inc. /s/ Avraham Gabay 01/17/2025